Japan is Breathing Life into the Stem Cell Space, Astellas Pharma (ALPMF) & Pluristem Therapeutics Inc. (PSTI) Are Benefiting
Japan is the stem cell capital of the world. From the Nobel winning efforts of Shinya Yamanaka in the field of mature to pluripotent stem cell reprogramming, to the STAP scandal and its suicide tarnished fallout, if there’s something to talk about in the sector, chances are it happened first in Japan.
Pluristem Therapeutics Inc. (PSTI) Given Buy Rating at HC Wainwright
Pluristem Therapeutics Therapeutics Inc. stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. They currently have a $3.50 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 134.90% from the company’s current price.
Several other research analysts have also issued reports on the company. FBR & Co restated an “outperform” rating and set a $6.00 target price on shares of Pluristem Therapeutics in a research report on Wednesday, June 22nd. Maxim Group restated a “buy” rating on shares of Pluristem Therapeutics in a research report on Tuesday, May 10th. Finally, Zacks Investment Research upgraded Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Wednesday, May 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $4.05.
INSIGHTEC, the leader in MR-guided Focused Ultrasound (MRgFUS) therapy, announced today that the FDA has approved its Exablate Neuro system for the non-invasive treatment of essential tremor (ET) in patients who have not responded to medication.
Exablate Neuro uses focused ultrasound waves to precisely target and ablate tissue deep within the brain with no incisions or implants. The treatment is done under Magnetic Resonance Imaging (MRI) guidance for real time treatment monitoring. The patient experiences immediate tremor improvement following the outpatient procedure. The treatment carries minimal risk of infection, bleeding or other surgical complications. The treatment requires a single session with no anesthesia, allowing patients to quickly return to normal activity.
Essential tremor is the most common movement disorder, affecting more than 5 million people in the United States, and millions more worldwide. Hand tremor is the most common symptom, but tremors can also affect the head, arms, voice, legs, and torso. For these patients, performing everyday tasks presents a challenge and impacts their quality of life.
Quote: "Zami and Yaky, two crooked colleagues that have
brought more than one company into bankruptcy."
Name one if you please! If not, you'd better apologize!
Mr. Sam Cohen, CEO of EVS, commented, “This is certainly a milestone for EVS. We have begun to see iBar make a significant contribution to our bottom line. When we began the development of this product, we knew there was a need and a payback for automation in this area. The fact that the vast majority of these orders are from existing iBar users demonstrates our solution satisfies both.”
Naw, S.S claimed to have
sold all EMITF holdings
(20K, imagine that) while
the total daily volume was
..... 3K. All in all, i think he
is hallucinating 95% of his
"We are encouraged by the momentum we are starting to build for our accounts payable solution, especially with mid-market companies," commented Michael Schrader, CEO Top Image Systems. "Our strong reputation for high quality invoice recognition and extraction, coupled with the recent release of our end-to-end Accounts Payable automation solution, is positioning us for growth."
Drop by drop the bucket shalt fill!
has signed an agreement for the sale of a 20,700 sqm plot of land in Lodz, Poland, to a residential developer, for #$%$2.4 million.
Another positive albeit smallish
step towards recovery!!!